— FDA clearance of investigational new drug (IND) application
— Initiation of multisite Phase 2 study in spring 2022
SEATTLE , April 18, 2022 /PRNewswire/ -- Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced clinical development progress for LMN-201, an investigational orally delivered cocktail to treat and prevent C. difficile infection (CDI). Achievements include FDA clearance of a planned Phase 2 study of LMN-201 and successful completion of a Phase 1 first-in-human study, which validated drug delivery of enteric capsules into the gut.
LMN-201 combines four therapeutic proteins—manufactured and orally delivered in the edible microorganism spirulina—that work synergistically to neutralize both the C. difficile bacterium and the toxin that causes its virulence. LMN-201 is the world's first complex biologic cocktail to enter human clinical trials and represents a significant advance in the field of polypharmacology. Lumen recently published its pre-clinical data on LMN-201 on bioRxiv, pending peer review.
"We are excited to mark these clinical milestones for LMN-201 and advance the development of a candidate that offers the potential to impact recurrent CDI, a major health problem worldwide," said Dr. Carl Mason , Lumen's head of clinical research. "Lumen's platform enables this novel approach of combining multiple therapeutic proteins into a single, low-cost, easily distributed and administered therapeutic. We are eager to advance LMN-201 into later stage clinical development."
The Phase 2 trial (NCT05330182) will begin enrolling approximately 375 patients at sites across the United States . Physicians interested in participating are encouraged to contact Lumen's clinical operations team at trials@lumen.bio. The double-blind, placebo-controlled study will evaluate the efficacy of LMN-201 in participants recently diagnosed with CDI receiving standard-of-care antibiotics.
The primary goal of the Phase 1 study of LMN-201 recently completed in Australia was to confirm the dissolution kinetics of enteric capsules designed to release LMN-201's therapeutic proteins at or before the terminal ileum, where C. difficile becomes established in most patients. The trial met its primary endpoint, indicating the capsules can successfully deliver LMN-201 where needed. Initial analysis also confirmed the therapeutic proteins were bioactive upon release and demonstrated robust stability against gastrointestinal protease digestion over time, meeting the exploratory endpoints. Lumen plans to publish full study results in a peer-reviewed journal after complete data analysis.
About C. difficile infection C. difficile infection (CDI) is the most common cause of health care-associated infections in U.S hospitals, where nearly half a million CDI cases occur each year. CDI is often considered a hospital-acquired infection, but community-associated CDI is on the rise and now comprises a majority of cases in some regions. Antibiotic therapy is typically successful for initial cases of CDI. However, 20%-40% of patients will suffer a recurrence, and the chance of additional episodes for these patients exceeds 40%. Currently available approaches for preventing CDI are hampered by high costs and inconvenient delivery (in most cases requiring either I.V. administration for traditional antibodies or bowel prep or enema for fecal microbiota transplant).
About LMN-201 LMN-201 is a cocktail of two classes of therapeutic proteins: the world's first complex biologic cocktail drug. The first class is comprised of three antibody-like proteins that bind and neutralize the bacterial toxin that is the main cause of the diarrhea and other severe symptoms of CDI. The second is an enzyme protein that destroys the cell wall of the C. difficile bacterium itself. The product is orally delivered in capsules and shelf stable, facilitating ready distribution to broader patient populations than is feasible with most other interventions available or in development for CDI.
To facilitate accessibility to the broadest possible patient population, these monoclonal proteins are expressed and delivered within whole spirulina biomass, a type of blue-green algae widely consumed as a nutritional supplement that Lumen has repurposed as a GMP biomanufacturing host as described in Lumen's recent paper in Nature Biotechnology. All four therapeutic proteins do their work without perturbing the patient's healthy GI microbiome. There has always been a certain illogic in using antibiotics to treat C. difficile infection, which is usually caused by prior antibiotic damage to the GI microbiome. Rather than treating CDI, which in most patients is easily cleared with generic antibiotics, therefore, LMN-201's primary purpose is to be delivered alongside and for a short period after antibiotics to prevent future bouts with CDI, a common side effect of antibiotics. Lumen recently published its pre-clinical data on LMN-201 on bioRxiv, pending peer review.
About Lumen Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for highly prevalent diseases—many of which currently lack any effective treatments. The company's unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale, and exponentially lower costs than current approaches. Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, cardiometabolic disease, inflammatory bowel disease, norovirus, and traveler's diarrhea. For more information, visit: www.lumen.bio.
Media Contact: Julie Rathbun +1.206.769.9219 jrathbun@lumen.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/lumen-bioscience-announces-clinical-advancement-of-lmn-201-for-c-difficile-infection-301526716.html
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
The company's current treatments dominate the cystic fibrosis market, but it's the pipeline that makes this stock so intriguing.
"I was in a medically induced coma for six weeks. There were times I was fully conscious, but I couldn't open my eyes, couldn't move a muscle, and couldn't speak. It was terrifying."View Entire Post ›
Hundreds of health care workers gathered outside a Nashville courthouse on Friday to protest the sentencing of a former Tennessee nurse facing up to eight years in prison for mistakenly causing the death of a patient
The pill has become an increasingly important tool in the nation’s defense against COVID-19 as mask mandates have lifted and people have returned to their non-distanced lives.
Dr. Anthony Fauci, the nation’s top infectious disease specialist, told The Root today that cases of the deadly Covid-19 virus are slowly rising again across the country and warned that Black Americans could be particularly at risk in the event a more aggressive variant should appear. Fauci spoke with The Root this afternoon where he clarified his own comments about where the nation stood on the status of the pandemic as the country nears the milestone of 1 million deaths from the virus, which o
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Intersect ENT, expanding the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.
Despite the popularity of vegan and vegetarian diets, a majority of people in the U.S. still do eat meat. In fact, according to a 2021 survey from Ipsos, 9 in 10 Americans currently include meat as part of their diet. With that in mind, it won't be hard for most to spot the symptoms of a concerning health condition that's becoming more and more of a problem thanks to another rising trend. Researchers are warning that the increasing prevalence of one pest across the country could have serious con
Feeling some dizziness? Experts say vertigo is serious and can be a sign of COVID-19. Here’s what to know about the symptom and when to see a doctor.
"It's creepy and gross. Stop that."View Entire Post ›
Korie Robertson shared her stance on abortion on a website that went down after publication: ‘The killing of babies in the womb should be legal in this country’
Deborah James has been honoured with a damehood after she inspired the nation and raised more than £4 million for her cancer research fundraising initiative in less than a week.
The 40-year-old said she was 'shocked' that she was even considered.
The city's largest tech employer also said it will be offering counseling from Burlingame-based metal-health service provider Lyra Health.
Christie Brinkley, 68, says “It’s not about the size of your thighs,” while posing with coral to talk body positivity, health, and weight loss advice.
Snacks for diabetics will satisfy without spiking blood sugars. Here, experts recommend healthy snacks for diabetics, like nuts, beef jerky, and cottage cheese.
Less well known pain-inducing conditions include trigeminal neuralgia- often described as an electric shock shooting through the face
(Reuters) -The U.S. Food & Drug Administration said on Friday it had approved Eli Lilly's injected drug tirzepatide, which has the brand name Mounjaro, to help improve blood sugar control in adults with type 2 diabetes. The FDA said Mounjaro, along with diet and exercise, improved blood sugar levels and was more effective than the other diabetes therapies with which it was compared in clinical studies. Mounjaro is designed to activate receptors for hormones involved in blood sugar control.
Nancy Cetel, MD and Joseph Weiss, MD discover the numerous health benefits offered by the luxurious and charming Cal-a-Vie Health Spa located in southern California. The post Cal-a-Vie Health Spa: The Ultimate Reset for Mind, Body and Spirit appeared first on Worth.
Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence. The drug was initially approved by the Food and Drug Administration (FDA) in the first quarter of 2020 as a treatment for adult schizophrenia. In late December, an additional indication, as a monotherapy or adjunct treatment for bipolar depression, was approved by the FDA.